User profiles for PATRIZIA MONDELLO
Patrizia MondelloMemorial Sloan Kettering Cancer Center Verified email at mskcc.org Cited by 2125 |
Kinase regulation of human MHC class I molecule expression on cancer cells
…, S Budhu, RS Gejman, G Mo, P Mondello… - Cancer immunology …, 2016 - AACR
The major histocompatibility complex I (MHC-1) presents antigenic peptides to tumor-specific
CD8 + T cells. The regulation of MHC-I by kinases is largely unstudied, even though many …
CD8 + T cells. The regulation of MHC-I by kinases is largely unstudied, even though many …
Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma
We have leveraged the molecular characterization of different types of CREBBP mutations
to define a rational approach for targeting these mutations through selective inhibition of …
to define a rational approach for targeting these mutations through selective inhibition of …
[HTML][HTML] Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse
Although methotrexate (MTX) is the most widely used therapy for central nervous system (CNS)
prophylaxis in patients with diffuse large B-cell lymphoma (DLBCL), the optimal regimen …
prophylaxis in patients with diffuse large B-cell lymphoma (DLBCL), the optimal regimen …
[HTML][HTML] Pim kinases in hematological malignancies: where are we now and where are we going?
P Mondello, S Cuzzocrea, M Mian - Journal of hematology & oncology, 2014 - Springer
The proviral insertion in murine (PIM) lymphoma proteins are a serine/threonine kinase
family composed of three isoformes: Pim-1, Pim-2 and Pim-3. They play a critical role in the …
family composed of three isoformes: Pim-1, Pim-2 and Pim-3. They play a critical role in the …
Cancer cachexia syndrome: pathogenesis, diagnosis, and new therapeutic options
P Mondello, M Mian, C Aloisi, F Famą… - Nutrition and …, 2015 - Taylor & Francis
Cancer anorexia-cachexia syndrome (CACS) is the most frequent paraneoplastic syndrome
occurring in half of all oncologic patients and is considered as a poor prognosticator. …
occurring in half of all oncologic patients and is considered as a poor prognosticator. …
[HTML][HTML] Lack of intrafollicular memory CD4+ T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma
P Mondello, A Fama, MC Larson, AL Feldman… - Blood cancer …, 2021 - nature.com
Despite a characteristic indolent course, a substantial subset of follicular lymphoma (FL)
patients has an early relapse with a poor outcome. Cells in the microenvironment may be a key …
patients has an early relapse with a poor outcome. Cells in the microenvironment may be a key …
[HTML][HTML] Insights into the tumor microenvironment of B cell lymphoma
WL Ng, SM Ansell, P Mondello - Journal of Experimental & Clinical Cancer …, 2022 - Springer
The standard therapies in lymphoma have predominantly focused on targeting tumor cells
with less of a focus on the tumor microenvironment (TME), which plays a critical role in …
with less of a focus on the tumor microenvironment (TME), which plays a critical role in …
Improved efficacy of tafasitamab plus lenalidomide versus systemic therapies for relapsed/refractory DLBCL: RE-MIND2, an observational retrospective matched …
GS Nowakowski, DH Yoon, A Peters, P Mondello… - Clinical Cancer …, 2022 - AACR
Purpose: In RE-MIND2 (NCT04697160), patient-level outcomes from the L-MIND study (NCT02399085)
of tafasitamab plus lenalidomide were retrospectively compared with patient-…
of tafasitamab plus lenalidomide were retrospectively compared with patient-…
Frontline treatment of diffuse large B‐cell lymphoma: Beyond R‐CHOP
P Mondello, M Mian - Hematological oncology, 2019 - Wiley Online Library
Although the majority of patients with diffuse large B‐cell lymphoma (DLBCL) can be cured
with the standard immunochemotherapy R‐CHOP, one‐third of them relapses with a dismal …
with the standard immunochemotherapy R‐CHOP, one‐third of them relapses with a dismal …
[HTML][HTML] Emerging markers of cachexia predict survival in cancer patients
Background Cachexia may occur in 40% of cancer patients, representing the major cause
of death in more than 20% of them. The aim of this study was to investigate the role of leptin, …
of death in more than 20% of them. The aim of this study was to investigate the role of leptin, …